Market Place
Sourcing Support
Syndax, Incyte pen chronic graft-versus-host disease collab
28 Sep 2021 //
FIERCEBIOTECH
Kadmon Announces U.S. Availability of REZUROCK for cGVHD
19 Aug 2021 //
PRESS RELEASE
Kadmon Announces belumosudil Added to NCCN Clinical Practice Guidelines
05 Aug 2021 //
PRESS RELEASE
Kadmon`s Chronic GVHD Drug Wins First FDA Approval for Company
20 Jul 2021 //
BIOSPACE
Kadmon shares jump on FDA approval of Rezurock for chronic GvHD
19 Jul 2021 //
CHEMDIV
Kadmon Announces U.S. FDA Has Extended the Review Period for Belumosudil
11 Mar 2021 //
PRESS RELEASE
Kadmon Announces 12 Month Data from Pivotal Trial of Belumosudil
07 Dec 2020 //
BIOSPACE
Kadmon to Present 12-Month Data from Pivotal Trial of Belumosudil
05 Nov 2020 //
KADMON
Kadmon Announces sNDA to the U.S. FDA for Belumosudil
30 Sep 2020 //
BUSINESSINSIADER
Kadmon files US application for belumosudil in GVHD
30 Sep 2020 //
SEEKING ALPHA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.